NovaBay Supports Legislation To Attack Antibiotic Resistance

CEO Cites Growing Crisis

EMERYVILLE, Calif., June 17, 2013 (GLOBE NEWSWIRE) -- Dr. Ron Najafi, Chairman and Chief Executive Officer of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) today announced NovaBay's support for legislation by U.S. Rep. Jim Matheson (D-UT) to attack the growing crisis of antibiotic resistance. NovaBay is a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides ®.

"NovaBay believes that there must be a multi-pronged, comprehensive approach to combating antimicrobial resistance and Rep. Matheson's bill is an important contribution," Dr. Najafi said. "We've reached a critical tipping point where we must replace antibiotics, whenever possible, with safe and effective alternatives that kill bacteria without developing resistance. "

The Strategies to Address Antimicrobial Resistance (STAAR) Act, H.R. 2285, is aimed at improving the understanding and monitoring of the cause and spread of antimicrobial resistant infections and improving antibiotic development, Matheson said.

 "Antimicrobial resistance is often caused by the overuse of antibiotics. My bill addresses this problem by calling for data collection on antibiotic use as well as research to combat so-called 'superbugs,'" Matheson said.

In the policy arena, NovaBay advocates for:
  • The elimination of tons of antibiotic that is used as livestock feed additive and which alone account for 80% of all antibiotics used and thrown away into our environment;
  • Developing non-antibiotic antimicrobial technologies with low probability of developing resistance and which would have the strong potential of replacing the antibiotics currently in use;
  • Rapid identification of bacteria so that the proper antibiotic can be prescribed and, when antibiotics are necessary, using the best practices to avoid generating resistant bacteria and transmitting them from one patient to another, and;
  • Proper disposal of leftover antibiotics and preventing them from getting into our landfills and sewers, which are brewing ground for antibiotic resistant bacteria.

NovaBay is committed to attacking the proliferation of antibiotic-resistant organisms through its pipeline of topical antimicrobial products that mimic the body's white blood cell mechanisms for fighting infection. 

If you liked this article you might like

3 Biotech Stocks Under $10 to Trade for Big Breakouts

Novabay Pharmaceuticals (NBY) Stock Spikes After FDA Approves Disinfection System

Insider Trading Alert - NBY, WPX And KTOS Traded By Insiders

Insider Trading Alert - EVTC, CRM And NBY Traded By Insiders

Insider Trading Alert - CGIX, NBY And BIOA Traded By Insiders